RANI

Rani Therapeutics Holdings Inc

May 15 • 04:00PM ET

1.08

-0.03 -2.70 %

Healthcare • Biotechnology • USA • Micro • NASD

May 15, 6:35 PMRani Therapeutics Holdings Inc reports fiscal Q1 2026 results with non-GAAP EPS $-0.04 (+82% YoY) and revenue $1.7M (+818% YoY), beats EPS and revenue estimates

Peers: ORMP ENTX XERS LPCN GOSS

| Held by: VTI VXF IWC IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.59	Insider Own	24.61%	Shs Outstand	97.62M	Perf Week	11.86%
Market Cap	133.69M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.00%	Shs Float	77.88M	Perf Month	17.52%
Enterprise Value	96.60M	PEG	-	EPS next Q	-0.05	Inst Own	28.46%	Short Float	11.49%	Perf Quarter	-12.90%
Income	-29.67M	P/S	82.02	EPS this Y	56.11%	Inst Trans	11.55%	Short Ratio	8.53	Perf Half Y	-49.06%
Sales	1.63M	P/B	3.19	EPS next Y	-23.14%	ROA	-62.30%	Short Interest	8.95M	Perf YTD	-20.00%
Book/sh	0.34	P/C	2.68	EPS next 5Y	16.83%	ROE	-169.56%	52W High	3.87 -72.09%	Perf Year	89.21%
Cash/sh	0.40	P/FCF	-	EPS past 3/5Y	29.57% 11.92%	ROIC	-83.02%	52W Low	0.39 179.07%	Perf 3Y	-73.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 28.73%	Gross Margin	44.89%	Volatility	8.38% 8.06%	Perf 5Y	-
Dividend TTM	-	EV/Sales	59.26	EPS Y/Y TTM	44.37%	Oper. Margin	-2345.93%	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.21	Sales Y/Y TTM	58.85%	Profit Margin	-1817.15%	RSI (14)	58.55	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.21	EPS Q/Q	74.41%	SMA20	12.10%	Beta	0.81	Target Price	7.50
Payout	-	Debt/Eq	0.13	Sales Q/Q	42.12%	SMA50	7.61%	Rel Volume	0.94	Prev Close	1.11
Employees	71	LT Debt/Eq	0.08	Earnings	May 15 AMC	SMA200	-4.49%	Avg Volume	1.05M	Price	1.08
IPO	Jul 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.11% 51.82%	Trades		Volume	988,710	Change	-2.70%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-26	Initiated	Lake Street	Buy	$9
Aug-02-24	Initiated	Oppenheimer	Outperform	$17
Jun-14-24	Initiated	Maxim Group	Buy	$15
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$10
Apr-17-23	Resumed	BTIG Research	Buy	$24
Oct-11-22	Initiated	UBS	Buy	$15
Jul-27-22	Initiated	H.C. Wainwright	Buy	$22
Jun-13-22	Initiated	Wedbush	Outperform	$28

May-15-26 04:05PM	Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition (GlobeNewswire)
May-12-26 04:05PM	Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference (GlobeNewswire)
Apr-09-26 07:00AM	Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy (GlobeNewswire) -6.15%
Mar-26-26 04:05PM	Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update (GlobeNewswire) -5.26% -24.94%
Mar-25-26 04:53PM	Rani Therapeutics Appoints Jesper Hoiland as Head of Strategy to Advance Corporate and Pipeline Prioritization (GlobeNewswire) +7.55%
09:19AM	Loading…
09:19AM	What To Expect From Rani Therapeutics Holdings Inc (RANI) Q4 2025 Earnings (GuruFocus.com)
Mar-19-26 04:05PM	Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Jan-28-26 07:00AM	Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer (GlobeNewswire)
Jan-24-26 08:45AM	Largest borrow rate increases among liquid names (TipRanks)
Jan-08-26 07:00AM	Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill for the Treatment of Obesity in Collaboration with ProGen (GlobeNewswire)
Nov-24-25 04:05PM	Rani Therapeutics to Participate in the Evercore Healthcare Conference (GlobeNewswire)
Nov-06-25 04:30PM	Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update (GlobeNewswire) -9.20% -11.01%
Oct-30-25 08:00AM	Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill Capsule at ObesityWeek 2025 (GlobeNewswire) -12.65%
Oct-26-25 06:05AM	H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential (Insider Monkey)
Oct-23-25 04:05PM	Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors (GlobeNewswire) -13.46% -12.92%
04:01PM	Loading…
04:01PM	Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire)
Oct-17-25 01:12PM	Why Rani Therapeutics (RANI) Stock Is Soaring Friday? (GuruFocus.com) +248.27%
07:31AM	Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire)
07:30AM	Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing (GlobeNewswire)
Aug-07-25 04:05PM	Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update (GlobeNewswire)
Jul-15-25 09:00AM	Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering (GlobeNewswire) -38.92%
Jul-14-25 05:00AM	Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery (GlobeNewswire) +8.45%
May-19-25 08:00AM	Rani Therapeutics Announces Research Agreement with Chugai (GlobeNewswire) +9.27%
May-13-25 04:05PM	Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update (GlobeNewswire) -21.42% +15.59%
Apr-01-25 10:55AM	Q4 2024 Rani Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:05AM	Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Mar-31-25 07:15PM	Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript (Seeking Alpha) -7.35%
04:05PM	Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update (GlobeNewswire)
Mar-26-25 04:05PM	Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill Capsule, to Subcutaneously Administered PG-102 (GlobeNewswire) -6.29%
Mar-25-25 06:00PM	Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
04:05PM	Loading…
Feb-05-25 04:05PM	Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill HC (GlobeNewswire) +5.11% +14.58%
Nov-14-24 08:00AM	Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:05PM	Rani Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-17-24 08:00AM	Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist (GlobeNewswire)
Oct-15-24 08:30AM	Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants (GlobeNewswire) -33.33%
Oct-13-24 06:01AM	Oppenheimer Predicts up to 740% Rally for These 2 Strong Buy Stocks (TipRanks)
Oct-08-24 04:05PM	Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire) +7.31%
Sep-03-24 04:05PM	Rani Therapeutics to Participate in September Investor Conferences (GlobeNewswire) -7.50%
Aug-06-24 04:05PM	Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update (GlobeNewswire)
Jul-29-24 04:05PM	Rani Therapeutics to Participate in August Investor Conferences (GlobeNewswire)
Jul-22-24 08:30AM	Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering (GlobeNewswire)
Jun-24-24 07:00AM	Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment (GlobeNewswire)
May-16-24 10:15AM	UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating (MT Newswires)
May-14-24 08:00AM	Rani Therapeutics to Participate in May Investor Conferences (GlobeNewswire) -5.40%
May-09-24 08:00AM	Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill Capsule at Digestive Disease Week 2024 (GlobeNewswire) -5.17%
May-07-24 09:06PM	Rani Therapeutics Q1 2024 Earnings: Financial Performance and Strategic Updates (GuruFocus.com)
May-06-24 09:55PM	RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q1 2024 (InvestorPlace) +5.73%
04:05PM	Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update (GlobeNewswire)
Mar-21-24 09:45AM	Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:35AM	Q4 2023 Rani Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-24 04:05PM	Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update (GlobeNewswire)
Mar-15-24 04:05PM	Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +6.25%
Feb-05-24 08:00AM	Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) (GlobeNewswire) +5.73%
Dec-14-23 08:00AM	Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist (GlobeNewswire)
Dec-07-23 12:00PM	What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock (Zacks)
Nov-08-23 05:53PM	Rani Therapeutics Holdings Inc (RANI) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com)
04:05PM	Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update (GlobeNewswire)
Nov-01-23 04:05PM	Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-25-23 08:00AM	The RaniPill Capsule, Rani Therapeutics' Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study (GlobeNewswire)
Oct-19-23 04:05PM	Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study (GlobeNewswire)
Oct-12-23 04:05PM	Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (GlobeNewswire)
Sep-18-23 08:00AM	Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43) (GlobeNewswire)
Sep-07-23 04:05PM	Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies (GlobeNewswire)
Sep-06-23 08:00AM	Rani Therapeutics to Participate in September Investor Conferences (GlobeNewswire)
Aug-11-23 04:05PM	Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update (GlobeNewswire)
Aug-04-23 04:05PM	Rani Therapeutics to Participate in August Investor Conferences (GlobeNewswire)
Jun-21-23 08:00AM	Rani Therapeutics Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference (GlobeNewswire)
Jun-08-23 08:00AM	Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference (GlobeNewswire)
Jun-05-23 08:00AM	Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105 (GlobeNewswire)
Jun-01-23 08:00AM	Rani Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-31-23 08:00AM	Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference (GlobeNewswire)
May-24-23 08:00AM	Rani Therapeutics Appoints Kate McKinley as Chief Business Officer (GlobeNewswire)
May-17-23 09:50AM	2 Strong Buy Penny Stocks With Over 400% Upside on the Horizon (TipRanks) +12.25%
May-10-23 04:05PM	Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update (GlobeNewswire) -8.84%
Apr-26-23 06:46AM	Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) last week's 14% decline must have disappointed private companies who have a significant stake (Simply Wall St.)
Apr-25-23 08:00AM	Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Apr-11-23 08:00AM	Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-23 07:12AM	Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 04:05PM	Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update (GlobeNewswire) -6.89%
Mar-16-23 04:05PM	Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire) +5.71%
Jan-09-23 08:30AM	Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment (GlobeNewswire)
Jan-05-23 04:05PM	Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update (GlobeNewswire) +8.12%
Dec-06-22 04:05PM	Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study (GlobeNewswire) +9.67%
Nov-17-22 05:30AM	Private companies among Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders, saw gain in holdings value after stock jumped 21% last week (Simply Wall St.)
Nov-10-22 05:25PM	Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-22 04:05PM	Rani Therapeutics to Present at the Stifel Healthcare Conference (GlobeNewswire)
Oct-28-22 09:55AM	Here's Why Rani Therapeutics Holdings, Inc. (RANI) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Oct-24-22 08:30AM	Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update (GlobeNewswire) -10.03%
Sep-27-22 09:06AM	8 Best Stocks to Buy According to Billionaire Marc Lasry (Insider Monkey)
Sep-06-22 04:05PM	Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 11:47PM	Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock (GlobeNewswire) -25.89% +37.55%
Aug-10-22 05:45PM	Rani Therapeutics Holdings, Inc. (RANI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
05:28PM	Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
04:28PM	Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update (GlobeNewswire)
04:23PM	Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis (GlobeNewswire)
Aug-08-22 08:30AM	Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill® Platform Advancement and Clinical Pipeline Development (GlobeNewswire)
Aug-03-22 07:48AM	Investors in Rani Therapeutics Holdings (NASDAQ:RANI) have made a return of 16% over the past year (Simply Wall St.)
May-11-22 04:05PM	Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update (GlobeNewswire) -5.75%
May-04-22 03:09PM	Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth (Simply Wall St.)

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Chief Technical OfficerMr. Alireza Javadi Ph.D.

Head of StrategyMr. Jesper Hoeiland M.Sc.

Vice President of Clinical DevelopmentMs. Arvinder Dhalla

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
IMRAN MIR A	Director	Oct 23 '25	Buy	0.60	2,083,334	1,260,417	2,083,334	Oct 27 07:24 PM
South Cone Investments Limited	10% Owner	Oct 21 '25	Sale	2.77	4,000,000	11,074,000	2,379,194	Oct 22 06:57 PM
South Cone Investments Limited	10% Owner	Oct 20 '25	Sale	2.41	1,923,000	4,637,314	6,379,194	Oct 22 06:57 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RANI

Rani Therapeutics Holdings Inc

Upgrade your Finviz experience